DERN CONTROL POINT INHIBITORS AND THEIR POSSIBILITIES FOR THE THERAPY OF METASTATIC UROTELIAL CANCER (4-8)

DOI: 10.31618/ESU.2413-9335.2020.6.74.761

Дата публикации статьи в журнале: 2020/06/14

Название журнала: Евразийский Союз Ученых — публикация научных статей в ежемесячном научном журнале, Выпуск: 74, Том: 6, Страницы в выпуске: 4-8

Автор: Tillyashaikhov M.N.
, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan, Tashkent

Автор: Kamishov S.V.
, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan, Tashkent

Автор: Boyko E.V.
, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan, Tashkent

Анотация: For a long time, chemotherapy remained the main treatment option for metastatic urothelial carcinoma (mUC). Over the past year, there have been revolutionary changes associated with the approval of five new drugs aimed at blocking the interaction between the surface protein of T‑lymphocytes PD‑1 and its ligands PD‑L1 and PD‑L2, resulting in the activation of the immune response. It is noteworthy that the anti‑PD‑1 antibody pembrolizumab demonstrated an increase in overall survival relative to chemotherapy in a randomized phase III trial in the second line with mUC. Based on this level 1 evidence pembrolizumab was approved by the US Food and Drug Administration (FDA). Nivolumab (antibody PD‑1) also demonstrated an increase in overall survival compared to historical control and was approved by FDA. Likewise, antibodies targeting PD‑L1, including atezolizumab, durvalumab and avelumab, received accelerated approval from the FDA as the second line of treatment for mUC. Some of these agents are approved in the first line by the results of phase II study (atezolizumab and pembolizumab received accelerated approval for first‑line treatment in patients not receiving cisplatin). Despite these many endorsements, clinical development of new biomarkers for selection of patients, who can get maximum advantages of immunotherapy and also for development the optimal therapy sequencing still are biggest and critical question for future investigation. The clinical introduction of biomarkers to determine optimal treatment of patients remains extremely important.

Ключевые слова: bladder cancer, PD-1,PD-L1,immunotherapy,atezolizumab,nivolumab,pembrolizumab,avelumab,durvalumab ,

Данные для цитирования: Tillyashaikhov M.N. Kamishov S.V. Boyko E.V. . DERN CONTROL POINT INHIBITORS AND THEIR POSSIBILITIES FOR THE THERAPY OF METASTATIC UROTELIAL CANCER (4-8) // Евразийский Союз Ученых — публикация научных статей в ежемесячном научном журнале. Медицинские науки. 2020/06/14; 74(6):4-8. 10.31618/ESU.2413-9335.2020.6.74.761

Скачать в формате PDF

Список литературы: 1.Surveillance, Epidemiology, and End Results Program. SEER stat fact sheets: kidney and renal pelvis cancer. Bethesda: National Cancer Institute; 2017. Available at http://seer.cancer.gov/ statfacts/html/urinb.html. 2.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Can‑cer J Clin. 2017 Jan;67 (1):7– 30. DOI: 10.3322/caac.21387. 3. Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; ESMO Guidelines Working Group. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow‑up. Ann Oncol. 2014 Sep;25 Suppl 3: iii40–8. DOI: 10.1093/annonc/mdu223 3.Milowsky MI, Rumble RB, Booth CM, Gilligan T, Eapen LJ, Hauke RJ, et al. Guideline on muscle‑invasive and metastatic bladder cancer (European Association of Urology guideline): American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2016 Jun 1;34 (16):1945–52. DOI: 10.1200/JCO.2015.65.9797 4.Ghasemzadeh A, Bivalacqua TJ, Hahn NM, Drake CG. New strategies in bladder cancer: a second coming for immunotherapy. Clin Cancer Res. 2016 Feb 15;22 (4):793–801. DOI: 10.1158/1078–0432.CCR‑15– 1135. 5. Ning YM, Suzman D, Maher VE, Zhang L, Tang S, Ricks T, et al. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‑Containing Chemotherapy. Oncologist. 2017 Jun;22 (6):743–749. DOI: 10.1634/theoncologist.2017– 0087 6.Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti‑PD‑L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov 27;515 (7528):558–62. DOI: 10.1038/nature13904. 7.Rosenberg JE, Hoffman‑Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum‑based chemotherapy: a single‑arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387 (10031):1909–20. DOI: 10.1016/S0140–6736 (16)00561–4. 9. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first‑line treatment in cisplatin‑ineligible patients with locally advanced and metastatic urothelial carcinoma: a single‑arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389 (10064):67–76. DOI: 10.1016/S0140–6736 (16)32455–2 8.Sharma P, Retz M, Siefker‑Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, singlearm, phase 2 trial. Lancet Oncol. 2017 Mar;18 (3):312–322. DOI: 10.1016/ S1470–2045 (17)30065–7. 9.Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second‑line therapy for advanced Urothelial carcinoma. N Engl J Med. 2017 Mar 16;376 (11):1015–1026. DOI: 10.1056/NEJMoa1613683. 10.Herbst RS, Baas P, Kim DW, Felip E, Pérez‑Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD‑L1‑positive, advanced non‑small‑cell lung cancer (KEYNOTE‑010): a randomised controlled trial. Lancet. 2016 Apr 11. 9;387 (10027):1540–50. DOI: 10.1016/S0140– 6736 (15)01281–7 12. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in advanced renal‑cell carcinoma. N Engl J Med. 2015 Nov 5;373 (19):1803–13. DOI: 10.1056/NEJMoa1510665 13. Balar A, Bellmunt J, O’Donnell PH, et al. Pembrolizumab (pembro) as firstline therapy for advanced/unresectable or metastatic urothelial cancer: preliminary results from the phase 2 KEYNOTE‑052 study. Ann Oncol. 2016; 27: LBA32_PR‑LBA_PR. 15. O’Donnell PH, Grivas P, Balar AV, et al. Biomarker findings and mature clinical results from KEYNOTE‑052: first‑line pembrolizumab (pembro) in cisplatinineligible advanced urothelial cancer (UC). J Clin Oncol. 2017;35:4502. 14. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN‑gamma‑related mRNA profile predicts clinical response to PD‑1 blockade. J Clin Invest. 2017 Aug 1;127 (8):2930–2940. DOI: 10.1172/JCI91190. 15.Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and efficacy of Durvalumab (MEDI4736), an anti‑programmed cell death Ligand‑1 immune checkpoint inhibitor, in patients with advanced Urothelial bladder cancer. J Clin Oncol. 2016 Sep 10;34 (26):3119–25. DOI: 10.1200/JCO.2016.67.9761. 16. Drake CG, Bivalacqua TJ, Hahn NM. Programmed cell death Ligand‑1 blockade in Urothelial bladder cancer: to select or not to select. J Clin Oncol. 2016 Sep 10;34 (26):3115–6. DOI: 10.1200/JCO.2016.68.4696 17. Hahn NM, Powles T, Massard C, et al. Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC). J Clin Oncol. 2017;35:4525. Aggen and Drake Journal for ImmunoTherapy of Cancer (2017). 18. Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, et al. Avelumab, an anti‑programmed death‑Ligand 1 antibody, in patients with refractory metastatic Urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017 Jul 1;35 (19):2117–2124. DOI: 10.1200/JCO.2016.71.6795 21. Patel MR, Ellerton JA, Infante JR, et al. Avelumab in patients with metastatic urothelial carcinoma: pooled results from two cohorts of the phase 1b JAVELIN solid tumor trial. J Clin Oncol. 2017;35:330. 19. Larkin J, Chiarion‑Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in untreated melanoma. N Engl J Med. 2015 Jul 2;373 (1):23–34. DOI: 10.1056/NEJMoa1504030. 20. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, et al. Nivolumab plus ipilimumab as first‑line treatment for advanced non‑small‑cell lung cancer (CheckMate 012): results of an open‑label, phase 1, multicohort study. Lancet Oncol. 2017 Jan;18 (1):31–41. DOI: 10.1016/S1470–2045 (16)30624–6 21. Sharma PCM, Calvo E, et al. Efficacy and safety of nivolumab plus ipilimumab in previously treated metastatic urothelial carcinoma: first results from the phase I/II CheckMate 032 study. J Clin Oncol. 2016;34 (15 suppl): 2016. 2016 SITC Annual Meeting; National Harbor, MD. 22. Apolo AB, Mortazavi A, Stein MN, et al. A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors. J Clin Oncol. 2017;35:4562. 23. Powles T, Galsky MD, Castellano D, et al. A phase 3 study of first‑line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable stage IV urothelial bladder cancer (UBC): DANUBE. J Clin Oncol. 2016;34: TPS4574–TPS. 24. Powles T, Gschwend JE, Loriot Y, et al. Phase 3 KEYNOTE‑361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer. J Clin Oncol. 2017;35: TPS4590–TPS. 25.Powles T, Gschwend JE, Loriot Y, et al. Pembrolizumab ± che‑motherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE‑361 trial. Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, mdx371.073. 26. Smith DC, Gajewski T, Hamid O, et al. Epacadostat plus pem‑brolizumab in patients with advanced urothelial carcinoma: preliminary phase I/II results of ECHO‑202/KEYNOTE‑037. J Clin Oncol. 2017;35:4503. 27. Rachel E, Sanborn MJP, Harriet M, Kluger, Callahan MK, Weise AM, et al. Clinical results with combination of anti‑CD27 agonist antibody, varlilumab, with anti‑PD1 antibody nivolumab in advanced cancer patients. Chicago: ASCO Annual Meeting 2017; 2017. 28. Infante JR, Ahlers CM, Hodi FS, et al. ENGAGE‑1: a first in hu‑man study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors. J Clin Oncol. 2016;34: TPS3107–TPS. 29. Wainberg ZA, Eisenberg PD, Sachdev JC, et al. Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD‑1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors. J Clin Oncol. 2016;34: TPS465– TPS.